How Do Interferons Induce an Antiviral State?
Interferons are signaling proteins secreted by virus-infected host cells that alert surrounding uninfected cells to establish a defensive barrier against infection. Once released into the extracellular environment, these cytokines bind to specific cell-surface receptors on nearby uninfected cells, activating the intracellular Janus kinase and signal transducer and activator of transcription pathway. This signaling cascade induces the transcription of hundreds of interferon-stimulated genes whose protein products collectively halt viral translation, degrade viral nucleic acids, inhibit viral transcription, and restrict particle release, thereby establishing an environment that limits viral replication and spread.
Initial Detection and Interferon Secretion
The induction of an antiviral state begins with the detection of viral components by pattern recognition receptors (PRRs) within an infected cell. Intracellular viral pathogen-associated molecular patterns (PAMPs), such as foreign double-stranded RNA (dsRNA) or cytoplasmic viral DNA, are recognized by cytosolic sensors (such as RIG-I-like receptors and cGAS) and endosomal Toll-like receptors (TLRs).
This detection triggers signaling cascades that phosphorylate and activate key transcription factors, primarily interferon regulatory factors (IRF3 and IRF7) and NF-κB. Once activated, these factors translocate to the nucleus to drive the transcription and secretion of Type I interferons (predominantly IFN-α and IFN-β) and Type III interferons (IFN-λ).
Receptor Binding and the JAK-STAT Signaling Cascade
Secreted interferons act in a paracrine manner by binding to high-affinity receptors located on the plasma membranes of neighboring, uninfected cells:
- Type I Interferons (IFN-α/β): Bind to the heterodimeric receptor complex consisting of IFNAR1 and IFNAR2, expressed ubiquitously across most nucleated cells.
- Type III Interferons (IFN-λ): Bind to a distinct receptor heterodimer formed by IFNLR1 and IL10Rβ, primarily localized to mucosal epithelial barriers and hepatocytes.
Ligand binding induces receptor dimerization, which brings together receptor-associated Janus kinases (JAK1 and TYK2). These kinases cross-phosphorylate and phosphorylate specific tyrosine residues on the cytoplasmic tails of the receptor chains, creating docking sites for downstream signaling mediators.
Members of the Signal Transducer and Activator of Transcription (STAT) family, specifically STAT1 and STAT2, dock at these sites and are subsequently phosphorylated by the Janus kinases. Phosphorylated STAT1 and STAT2 form a heterodimer and bind to Interferon Regulatory Factor 9 (IRF9) in the cytoplasm, assembling a heterotrimeric transcriptional complex known as Interferon-Stimulated Gene Factor 3 (ISGF3).
ISGF3 translocates into the nucleus and binds to conserved Interferon-Stimulated Response Elements (ISRE) within the promoter regions of target genes, initiating the robust transcription of hundreds of Interferon-Stimulated Genes (ISGs).
Key Interferon-Stimulated Genes (ISGs) and Antiviral Mechanisms
The coordinated expression of ISGs establishes the multifaceted antiviral state in the target cell. Several principal ISG-encoded enzymes directly target and disrupt the viral replication cycle:
1. 2'-5'-Oligoadenylate Synthetase (OAS) and Ribonuclease L (RNase L)
OAS enzymes act as sensors that are activated upon binding to viral double-stranded RNA. Upon activation, OAS synthesizes short 2',5'-linked oligoadenylates from ATP. These unusual oligonucleotides act as second messengers that bind to and activate Ribonuclease L (RNase L), a latent endoribonuclease. Active RNase L degrades both viral and host single-stranded RNA, thereby halting viral replication and generating RNA cleavage products that further amplify interferon signaling.
2. Protein Kinase R (PKR)
Protein Kinase R is synthesized in an inactive, monomeric state and dimerizes upon binding to viral dsRNA. Autophosphorylation activates PKR, enabling it to phosphorylate the alpha subunit of eukaryotic translation initiation factor 2 (eIF-2α). Phosphorylation of eIF-2α inhibits translation initiation, shutting down both host and viral protein synthesis to starve the incoming virus of protein-building machinery.
3. Mx GTPases (MxA and MxB)
The myxovirus resistance (Mx) dynamin-like GTPases form oligomeric ring-like structures around viral nucleocapsids and components. In humans, MxA recognizes and traps nucleocapsid structures of various RNA viruses, preventing their transport to the nucleus or blocking viral genome replication. MxB specifically restricts retroviruses, such as HIV-1, by binding the viral capsid and preventing nuclear import and uncoating of the viral pre-integration complex.
4. ISG15 (Interferon-Stimulated Gene 15)
ISG15 is a ubiquitin-like modifier that covalently conjugates to target host and viral proteins in a process known as ISGylation. This modification alters protein stability, prevents the oligomerization of viral structural proteins, and modulates host immune signaling components to enhance antiviral defenses.
5. Tetherin (BST-2)
Tetherin is a transmembrane protein that physically anchors budding enveloped viruses to the host cell surface. By preventing the release and dissemination of newly formed virions, Tetherin facilitates the entrapment of pathogens for subsequent degradation or immune clearance.
6. IFIT and IFITM Families
Interferon-induced proteins with tetratricopeptide repeats (IFITs) selectively bind uncapped, 5'-triphosphate, or 2'-O-unmethylated viral RNA, blocking translation initiation and viral replication. Interferon-induced transmembrane proteins (IFITMs) localize to endosomal and plasma membranes, altering membrane fluidity to block viral entry and membrane fusion.
Biological Significance in Host Defense
By priming uninfected neighboring cells prior to viral entry, the interferon response creates a non-permissive tissue microenvironment. Incoming viral particles encounter cells pre-equipped with dormant and active enzymatic defenses capable of destroying viral genomes, stalling protein translation, and preventing viral assembly. This mechanism slows the velocity of viral dissemination across host tissues, containing the infection until adaptive immune mechanisms can be mobilized.